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In patients with coronary heart disease, revascularization can improve symptoms and, in certain high-risk subgroups, may improve prognosis. Coronary angiog-raphy provides anatomic information, and the physiological significance of a 
stenosis can be determined using fractional flow reserve (FFR). Decisions on the 
need for and mode of revascularization can be optimized using FFR. However, this 
process involves administering adenosine to induce hyperemia. Generally, this is 
well tolerated, but in some healthcare systems, adenosine is either not licensed, 
unavailable, or expensive, limiting the use of FFR-guided management.
Recently, alternative approaches to FFR have emerged, including resting indi-
ces such as Pd/Pa and instantaneous wave free ratio (iFR).1,2 Hybrid algorithms 
incorporating a resting index reduce the need for adenosine by ≈50% or a hy-
brid algorithm utilizing contrast FFR reduces adenosine use even further (~65%).3 
These diagnostic approaches represent clinically useful advances provided health 
outcomes are not compromised.
The DEFINE-FLAIR trial (Functional Lesion Assessment of Intermediate Stenosis 
to Guide Revascularisation)1 and the iFR-SWEDE-HEART trial (Instantaneous Wave-
free Ratio versus Fractional Flow Reserve in Patients with Stable Angina Pectoris or 
Acute Coronary Syndrome)2 compared iFR- versus FFR-guided management using 
binary cutoff values in both groups. The primary composite outcome of death, 
myocardial infarction (MI), and urgent revascularization at 12 months and the 
noninferiority designs were consistent across both trials. Overall, an iFR-guided 
strategy was associated with a lower use of revascularization, and the primary end 
point results of both trials met the prespecified noninferiority criteria. The numeri-
cally dominant component of the primary outcome was unplanned revasculariza-
tion. The rationale of our study was to assess the risk of death and MI between the 
iFR- and FFR-guided groups in a pooled analysis of these trials.
Our objective was to undertake a meta-analysis of the pooled events for death 
and MI in the DEFINE-FLAIR and iFR-SWEDE-HEART trials. The principal summary 
measure was the risk ratio (95% confidence interval [CI] and P value) calculated 
for each study. Meta-analysis estimates were calculated from a random effects 
model using the REML method. Fixed effects analyses using the Cochrane-Man-
tel-Haenzel method produced near identical results (not shown). I2 was used to 
measure the consistency of the meta-analysis. The analysis was conducted with R 
(version 3.10) using the metaphor (https://CRAN.R-project.org/package=metafor) 
and rmeta (https://CRAN.R-project.org/package=rmeta) packages.
The study characteristics and results are summarized in the Table. In total, 
160 deaths or MI events occurred in 4345 participants during the 12 months 
after randomization. Of these events, 90 occurred in the iFR group (n=2159), 
and 70 events occurred in the FFR group (n=2186) (hazard ratio, 1.30; 95% CI, 
0.96‒1.77; P=0.09). Considering the hazard ratio for death or MI, the lower CI 
limit crosses unity. The upper CI limit indicates that the risk of this adverse out-
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come could be ≤77% greater for iFR guidance com-
pared with FFR guidance. No evidence of heterogene-
ity was found between the 2 studies (I2 was 0% and χ2 
P>0.5 for all analyses and unplanned revascularizations 
were I2=16% and χ2 P=0.28). We identified a risk of 
bias in these trials because any coronary revasculariza-
tion after 60 days was defined as unplanned, but this 
procedure (a primary outcome event) was ordered by a 
physician who may have had knowledge of the treat-
ment group assignment because of the open-label trial 
design (DEFINE-FLAIR attempted to blind the treating 
clinician to whether iFR or FFR was performed, but this 
was not done in iFR-SWEDE-HEART).
In the DEFINE-FLAIR and iFR-SWEDE-HEART trials, 
we observed a numeric excess of death or MI events in 
the iFR compared with the FFR groups. Directional con-
sistency exists for this outcome in both trials and also 
when considering death and MI as separate outcomes. 
Both trials have relevant design limitations. First, be-
cause of the concordance between iFR and FFR in 80% 
of patients, the randomized strategy could only influ-
ence outcome in 20% of trial participants, diluting the 
power of both studies to detect a clinically meaningful 
difference in outcomes. Second, in the context of other 
evidence, the discordance between iFR and FFR is great-
est in stenoses of the left main and proximal coronary 
arteries,4,5 which is where revascularization may confer a 
survival advantage. The distribution of coronary disease 
in the trial participants has not been reported. Finally, 
the populations studied in both trials were at relatively 
low cardiovascular risk, with incidence of death, MI, and 
repeat revascularization at 1 year ≈50% of what was 
observed in the FAME trial (Fractional Flow Reserve ver-
sus Angiography for Guiding Percutaneous Coronary In-
Table. Unplanned Revascularization and Spontaneous Adverse Outcomes at 12 Months 
in DEFINE-FLAIR (Functional Lesion Assessment of Intermediate Stenosis to Guide 
Revascularisation) and iFR-SWEDEHEART (Instantaneous Wave-free Ratio versus Fractional 
Flow Reserve in Patients with Stable Angina Pectoris or Acute Coronary Syndrome) Trials
iFR n (%) FFR n (%) Risk Ratio 95% CI P Value
Unplanned revascularization
 DEFINE-FLAIR 46 (4.0) 63 (5.3) 0.75 (0.52‒1.09) 0.13
 iFR-SWEDEHEART 47 (4.6) 46 (4.6) 1.02 (0.68‒1.51) 0.94
 Overall   0.87 (0.65‒1.16) 0.34
Test for heterogeneity: χ2 = 1.18 df=1 (P=0.277), I2 = 15.6%
Nonfatal myocardial infarction
 DEFINE-FLAIR 31 (2.7) 28 (2.4) 1.14 (0.69‒1.89) 0.61
 iFR-SWEDEHEART 22 (2.2) 17 (1.7) 1.29 (0.69‒2.41) 0.43
 Overall   1.20 (0.81‒1.77) 0.37
Test for heterogeneity: χ2 = 0.09 df=1 (P=0.767), I2 = 0%
Death
 DEFINE-FLAIR 22 (1.9) 13 (1.1) 1.74 (0.88‒3.44) 0.11
 iFR-SWEDEHEART 15 (1.5) 12 (1.2) 1.24 (0.59‒2.64) 0.57
 Overall   1.50 (0.90‒2.48) 0.12
Test for heterogeneity: χ2 = 0.42 df=1 (P=0.516), I2 = 0%
Death or myocardial infarction
 DEFINE-FLAIR 53 (4.6) 41 (3.5) 1.33 (0.89‒1.98) 0.16
 iFR-SWEDEHEART 37 (3.7) 29 (2.9) 1.27 (0.79‒2.05) 0.33
 Overall   1.30 (0.96‒1.77) 0.09
The DEFINE-FLAIR trial (Functional Lesion Assessment of Intermediate Stenosis to Guide Revascularisation) randomized 
2492 participants, and primary outcome data were presented for 2330 (93%) (iFR group, n=1148, and FFR group, n=1182, 
respectively). Ninety-five participants in the iFR group were withdrawn from the study before or at 1 year, and 71 participants 
were withdrawn in the FFR group. The iFR-SWEDEHEART trial (Instantaneous Wave-free Ratio versus Fractional Flow Reserve in 
Patients with Stable Angina Pectoris or Acute Coronary Syndrome) randomized 2037 participants, and primary outcome data 
were available for 2019 (99%) (iFR group, n=1012, and FFR group, n=1007, respectively). Test for heterogeneity: χ2 = 0.02 df=1 
(P=0.886), I2 = 0%.
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tervention), highlighting the limited power for detecting 
any difference in clinically important health outcomes 
between the 2 strategies in the current trials.
In conclusion, in a pooled meta-analysis of the DE-
FINE-FLAIR and iFR-SWEDE-HEART trials, a numeric ex-
cess of death and MI events occurred in the iFR group 
that is not statistically significant and, therefore, hypoth-
esis generating. Considering death and MI, iFR-guided 
management may not be noninferior to FFR-guided 
management. Further research seems warranted.
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